The impact of health technology made simple...

...from the implications of new medical procedures, technologies and policies...

...to measuring their impact on current clinical practices...

...through close collaboration with health care professionals, researchers, and regulators.

Vital Transformation is a small, unique consultancy focused on addressing the challenges of today’s modern healthcare system. We partner with your organisation to help you find answers to hard to solve problems.

  • Real World Economic Analysis

  • Market Research and Access

  • Horizon Scanning

  • Branding

  • Communications

Contact us to learn how Vital Transformation can help your organisation.

LATEST RESEARCH

Investing in EU Biotech IP – What Works?

Vital Transformation released its newest research at the European Health Forum Gastein on October 4th, 2018. Our project analysed 116 EU biotech start-ups from the period of 2001 – 2007 through September 21, 2018 from the UK, Netherlands, Belgium, and Spain. We focused on companies developing medicinal products for human consumption. In this work, we compared the impact of IPOs (stock market listings), private investors, and direct EU funding on their success or failure.

LATEST COMMUNICATIONS

Our Communication Services

Founded in 2007 by the FDA and Duke University, the Clinical Trials Transformation Initiative (CTTI) has as its mission to develop and drive the adoption of practices that will increase the quality and efficiency of clinical trials. Pamela Tenaerts, CTTI’s Executive Director, has a broad international perspective given her previous life running large international clinical research at KU Leuven, and we were fortunate to catch up with her at the IMI Stakeholder Workshop in Brussels to discuss how to improve clinical research.

More Info

Find all our communication projects on Better Science, Better Health

MORE RESEARCH

DIA Global 2018: Value Pricing Bootcamp: A Crash Course in How to Use Real World Evidence to Better Measure Outcomes and Evaluate New Innovative Therapies


24th June 2018, Boston, USA



Duane Schulthess, Managing Director of Vital Transformation, and Luca Pani, former Director General of the Italian Medicine's Agency and currently a Faculty Member at the University of Miami, will run a 3 hour and 15 minute Short Course outlining how best to harness RWE to better understand the price, value, and impact of next generation therapies.

Real world big data for clinical research and drug development

30th December, 2017



The objective of this paper is to identify the extent to which real world data (RWD) is being utilized, or could be utilized, at scale in drug development. Through screening peer-reviewed literature, we have cited specific examples where RWD can be used for biomarker discovery or validation, gaining a new understanding of a disease or disease associations, discovering new markers for patient stratification and targeted therapies, new markers for identifying persons with a disease, and pharmacovigilance.

Medicines Adaptive Pathways to Patients (MAPPs): A Story of International Collaboration Leading to Implementation

21st October, 2015



After nearly a decade of discussion, analysis, and development, the Medicines Adaptive Pathways to Patients (MAPPs) initiative is beginning to see acceptance from regulators, industry, patients, and payers, with the first live pilot project initiated under the guidance of the European Medicines Agency in 2014.

VITAL HEALTH PODCASTS

SUBSCRIBE

NEWSLETTER

Register now to receive all the latest updates from Vital Transformation including our research, podcasts and more…

Sign Up

TWEETS

Our clients include many of the world’s leading health care organisations.

NEWSLETTER SIGN UP

* required
 

GET REAL

EMIF

MIT

PHARMA

EFPIA

Consultancies

MEDIA

VT Health

DGS Outlook

EBE

ADAPT SMART

 

Click here to read our Privacy Statement.